留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

雌激素及其受体在非酒精性脂肪性肝病发生发展中的作用机制

彭娟 李良平

彭娟, 李良平. 雌激素及其受体在非酒精性脂肪性肝病发生发展中的作用机制[J]. 临床肝胆病杂志, 2021, 37(2): 467-470. DOI: 10.3969/j.issn.1001-5256.2021.02.046
引用本文: 彭娟, 李良平. 雌激素及其受体在非酒精性脂肪性肝病发生发展中的作用机制[J]. 临床肝胆病杂志, 2021, 37(2): 467-470. DOI: 10.3969/j.issn.1001-5256.2021.02.046
PENG J, LI LP. Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease [J]. J Clin Hepatol, 2021, 37(2): 467-470. DOI: 10.3969/j.issn.1001-5256.2021.02.046
Citation: PENG J, LI LP. Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease [J]. J Clin Hepatol, 2021, 37(2): 467-470. DOI: 10.3969/j.issn.1001-5256.2021.02.046

雌激素及其受体在非酒精性脂肪性肝病发生发展中的作用机制

DOI: 10.3969/j.issn.1001-5256.2021.02.046
基金项目: 

四川省卫计委重点课题 16ZD024

详细信息
    作者简介:

    彭娟(1995—),女,主要从事非酒精性脂肪性肝病研究

    通讯作者:

    李良平,18981838872@163.com

  • 作者贡献声明:彭娟负责收集、阅读、筛选文献,撰写论文;李良平负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R575.5

Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease

  • 摘要: 非酒精性脂肪性肝病(NAFLD)的发病率剧增,目前仍然缺乏有效的药物治疗。虽然对NAFLD发病相关机制研究取得了巨大进展,但对NAFLD的性别差异的理解依然不够。雌激素作为重要的性激素,通过调节情绪及能量稳态、脂肪组织功能及分布、炎症反应、胰岛素抵抗、肝脂蓄积、肝脏免疫等影响NAFLD的发生及发展。充分认识雌激素及雌激素受体在NAFLD中的作用机制,为NAFLD的治疗提供新思路。
  • [1] SEEBACHER F, ZEIGERER A, KORY N, et al. Hepatic lipid droplet homeostasis and fatty liver disease[J]. Semin Cell Dev Biol, 2020. [Epub ahead of print]
    [2] TOBARI M, HASHIMOTO E. Characteristic features of nonalcoholic fatty liver disease in japan with a focus on the roles of age, sex and body mass index[J]. Gut Liver, 2020.[Epub ahead of print]
    [3] SAYINER M, YOUNOSSI ZM. Nonalcoholic steatohepatitis is becoming a top indication for liver transplantation worldwide[J]. Liver Transpl, 2019, 25(1): 10-11. DOI: 10.1002/lt.25387
    [4] YANG Z, FU BS. Research status of liver transplantation in the treatment of non-alcoholic fatty liver disease[J]. Ogran Transplantation, 2020, 11(3): 419-423. (in Chinese) DOI: 10.3969/j.issn.1674-7445.2020.03.017

    杨洲, 傅斌生. 肝移植治疗非酒精性脂肪性肝病的研究现状[J]. 器官移植, 2020, 11(3): 419-423. DOI: 10.3969/j.issn.1674-7445.2020.03.017
    [5] JIANG YZ, NIE HM, WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2019, 35(11): 2588-2591.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.11.044

    姜煜资, 聂红明, 汪蓉. 非酒精性脂肪性肝病的发病机制[J]. 临床肝胆病杂志, 2019, 35(11): 2588-2591. DOI: 10.3969/j.issn.1001-5256.2019.11.044
    [6] LONARDO A, NASCIMBENI F, BALLESTRI S, et al. Sex differences in nonalcoholic fatty liver disease: State of the art and identification of research gaps[J]. Hepatology, 2019, 70(4): 1457-1469. DOI: 10.1002/hep.30626
    [7] LEE, C, KIM J, JUNG Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Cells, 2019, 8(10): 1259. DOI: 10.3390/cells8101259
    [8] ESTRADA CM, GHISAYS V, NGUYEN ET, et al. Estrogen signaling in the medial amygdala decreases emotional stress responses and obesity in ovariectomized rats[J]. Horm Behav, 2018, 98: 33-44. DOI: 10.1016/j.yhbeh.2017.12.002
    [9] QIU S, VAZQUEZ JT, BOULGER E, et al. Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males[J]. Sci Rep, 2017, 7(1): 1661. DOI: 10.1038/s41598-017-01937-4
    [10] VANDEL J, DUBOIS-CHEVALIER J, GHEERAERT C, et al. Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH)[J]. Hepatology, 2020.[Epub ahead of print]
    [11] GROSSMANN M, WIERMAN ME, ANGUS P, et al. Reproductive endocrinology of nonalcoholic fatty liver disease[J]. Endocr Rev, 2019, 40(2): 417-446. DOI: 10.1210/er.2018-00158
    [12] HART-UNGER S, ARAO Y, HAMILTON KJ, et al. Hormone signaling and fatty liver in females: Analysis of estrogen receptor α mutant mice[J]. Int J Obes (Lond), 2017, 41(6): 945-954. DOI: 10.1038/ijo.2017.50
    [13] ASCHA MS, HANOUNEH IA, LOPEZ R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2010, 51(6): 1972-1978. DOI: 10.1002/hep.23527
    [14] PALMISANO BT, ZHU L, STAFFORD JM. Role of estrogens in the regulation of liver lipid metabolism[J]. Adv Exp Med Biol, 2017, 1043: 227-256. DOI: 10.1007%2F978-3-319-70178-3_12
    [15] WINN NC, JURRISSEN TJ, GRUNEWALD ZI, et al. Estrogen receptor-α signaling maintains immunometabolic function in males and is obligatory for exercise-induced amelioration of nonalcoholic fatty liver[J]. Am J Physiol Endocrinol Metab, 2019, 316(2): e156-e167. DOI: 10.1152/ajpendo.00259.2018
    [16] WANG X, LU Y, WANG E, et al. Hepatic estrogen receptor α improves hepatosteatosis through upregulation of small heterodimer partner[J]. J Hepatol, 2015, 63(1): 183-190. DOI: 10.1016/j.jhep.2015.02.029
    [17] GUILLAUME M, RIANT E, FABRE A, et al. Selective liver estrogen receptor α modulation prevents steatosis, diabetes, and obesity through the anorectic growth differentiation factor 15 hepatokine in mice[J]. Hepatol Commun, 2019, 3(7): 908-924. DOI: 10.1002/hep4.1363
    [18] ZHANG B, ZHANG CG, JI LH, et al. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells[J]. J Gastroenterol Hepatol, 2018, 33(3): 747-755. DOI: 10.1111/jgh.13976
    [19] MAUVAIS-JARVIS F, ARNOLD AP, REUE K. A guide for the design of pre-clinical studies on sex differences in metabolism[J]. Cell Metab, 2017, 25(6): 1216-1230. DOI: 10.1016/j.cmet.2017.04.033
    [20] XU Y, NEDUNGADI TP, ZHU L, et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction[J]. Cell Metab, 2011, 14(4): 453-465. DOI: 10.1016/j.cmet.2011.08.009
    [21] GONZÁIEZ-GARCÍA I, CONTRERAS C, ESTÉVEZ-SALGUERO Á, et al. Estradiol regulates energy balance by ameliorating hypothalamic ceramide-induced ER stress[J]. Cell Rep, 2018, 25(2): 413-423. e5. DOI: 10.1016/j.celrep.2018.09.038
    [22] BOLDARINE VT, PEDROSO AP, NETO N, et al. High-Fat diet intake induces depressive-like behavior in ovariectomized rats[J]. Sci Rep, 2019, 9(1): 10551. DOI: 10.1038/s41598-019-47152-1
    [23] ESTRADA CM, GHISAYS V, NGUYEN ET, et al. Estrogen signaling in the medial amygdala decreases emotional stress responses and obesity in ovariectomized rats[J]. Horm Behav, 2018, 98: 33-44. DOI: 10.1016/j.yhbeh.2017.12.002
    [24] GERDTS E, REGITZ-ZAGROSEK V. Sex differences in cardiometabolic disorders[J]. Nat Med, 2019, 25(11): 1657-1666. DOI: 10.1038/s41591-019-0643-8
    [25] FAULKNER JL, BELIN DE CHANTEMÈLE EJ. Sex hormones, aging and cardiometabolic syndrome[J]. Biol Sex Differ, 2019, 10(1): 30. DOI: 10.1186/s13293-019-0246-6
    [26] LINK JC, REUE K. Genetic basis for sex differences in obesity and lipid metabolism[J]. Annu Rev Nutr, 2017, 37: 225-245. DOI: 10.1146/annurev-nutr-071816-064827
    [27] KLEIN SL, MARRIOTT L, FISH EN. Sex-based differences in immune function and responses to vaccination[J]. Trans R Soc Trop Med Hyg, 2015, 109(1): 9-15. DOI: 10.1093/trstmh/tru167
    [28] KLEIN SL, MORGAN R. The impact of sex and gender on immunotherapy outcomes[J]. Biol Sex Differ, 2020, 11(1): 24. DOI: 10.1186/s13293-020-00301-y
    [29] MAUVAIS-JARVIS F, MANSON JE, STEVENSON JC, et al. Menopausal hormone therapy and type 2 diabetes prevention: Evidence, mechanisms, and clinical implications[J]. Endocr Rev, 2017, 38(3): 173-188. DOI: 10.1210/er.2016-1146
    [30] CHEN JQ, CAMMARATA PR, BAINES CP, et al. Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications[J]. Biochim Biophys Acta, 2009, 1793(10): 1540-1570. DOI: 10.1016/j.bbamcr.2009.06.001
    [31] GALMÉS-PASCUAL BM, MARTÍNEZ-CIGNONI MR, MORÁN-COSTOYA A, et al. 17β-estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance[J]. Free Radic Biol Med, 2020, 150: 148-160. DOI: 10.1016/j.freeradbiomed.2020.02.016
    [32] LIU S, MAUVAIS-JARVIS F. Minireview: Estrogenic protection of beta-cell failure in metabolic diseases[J]. Endocrinology, 2010, 151(3): 859-864. DOI: 10.1210/en.2009-1107
    [33] de BANDT JP, JEGATHEESAN P, TENNOUNE-EI-HAFAIA N. Muscle loss in chronic liver diseases: The example of nonalcoholic liver disease[J]. Nutrients, 2018, 10(9): 1195. DOI: 10.3390/nu10091195
    [34] YU J, MARSH S, HU J, et al. The pathogenesis of nonalcoholic fatty liver disease: Interplay between diet, gut microbiota, and genetic background[J]. Gastroenterol Res Pract, 2016, 2016: 2862173. http://downloads.hindawi.com/journals/grp/2016/2862173.xml
    [35] CHOUDHARY NS, KUMAR N, DUSEJA A. Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease[J]. J Clin Exp Hepatol, 2019, 9(6): 731-739. DOI: 10.1016/j.jceh.2019.06.004
    [36] VIDELA LA, PETTINELLI P. Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity[J]. PPAR Res, 2012, 2012: 107434. http://www.ncbi.nlm.nih.gov/pubmed/23304111
    [37] VACCA M, ALLISON M, GRIFFIN JL, et al. Fatty acid and glucose sensors in hepatic lipid metabolism: Implications in NAFLD[J]. Semin Liver Dis, 2015, 35(3): 250-261. DOI: 10.1055/s-0035-1562945
    [38] KLEINERT M, CLEMMENSEN C, HOFMANN SM, et al. Animal models of obesity and diabetes mellitus[J]. Nat Rev Endocrinol, 2018, 14(3): 140-162. DOI: 10.1038/nrendo.2017.161
    [39] LI FJ, WEI SN, WANG LY, et al. Estrogen reduces lipid deposition in liver cells by inhibiting Perilipin 2[J]. J Cardiovascular Pulmonary Dis, 2018, 37(7): 687-691. (in Chinese) DOI: 10.3969/j.issn.1007-5062.2018.07.022

    李凤娟, 魏苏宁, 王绿娅, 等. 雌激素抑制脂滴包被蛋白Perilipin2减少肝细胞脂质沉积[J]. 心肺血管病杂志, 2018, 37(7): 687-691. DOI: 10.3969/j.issn.1007-5062.2018.07.022
    [40] BARB D, BRIL F, KALAVALAPALLI S, et al. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes[J]. J Clin Endocrinol Metab, 2019, 104(8): 3327-3336. DOI: 10.1210/jc.2018-02414
    [41] ALISI A, CECCARELLI S, PANERA N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease[J]. Plos One, 2013, 8(6): e67160. DOI: 10.1371/journal.pone.0067160
    [42] SANTOS-MARCOS JA, HARO C, VEGA-ROJAS A, et al. Sex differences in the gut microbiota as potential determinants of gender predisposition to disease[J]. Mol Nutr Food Res, 2019, 63(7): e1800870. DOI: 10.1002/mnfr.201800870
    [43] SANTOS-MARCOS JA, RANGEL-ZUÑIGA OA, JIMENEZ-LUCENA R, et al. Influence of gender and menopausal status on gut microbiota[J]. Maturitas, 2018, 116: 43-53. DOI: 10.1016/j.maturitas.2018.07.008
    [44] ACHARYA KD, GAO X, BLESS EP, et al. Estradiol and high fat diet associate with changes in gut microbiota in female ob/ob mice[J]. Sci Rep, 2019, 9(1): 20192. DOI: 10.1038/s41598-019-56723-1
    [45] GANZ M, CSAK T, SZABO G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation[J]. World J Gastroenterol, 2014, 20(26): 8525-8534. DOI: 10.3748/wjg.v20.i26.8525
  • 加载中
计量
  • 文章访问数:  22
  • HTML全文浏览量:  4
  • PDF下载量:  10
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-07-08
  • 修回日期:  2020-08-18
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回